Benefits
Joint comfort and mobility support
In one small 28-day randomized, double-blind, placebo-controlled trial (90 adults aged 18 to 60 with functional knee pain), a standardized Astragalus membranaceus root extract at 480 mg/day cut walking-test knee pain by about 30% and improved WOMAC and stair-climb scores versus placebo. This is one small trial of the botanical, run on a different supplier's extract at a higher dose than the 200 mg JointIQ serving, so read it as supportive but not confirmatory for JointIQ itself.
Connective tissue maintenance
In cultured human chondrocytes, Astragalus membranaceus root extract lowered inflammatory cytokines (IL-6, IL-1beta, IL-8) and matrix-degrading enzymes (MMP-3, MMP-13, ADAMTS-5) driven by TNF-alpha, and laboratory work reports increased type II collagen synthesis. These are cell-culture findings, not measured cartilage outcomes in people.
Single-botanical joint option
JointIQ is one standardized Astragalus root extract rather than a stack of collagen, glucosamine and MSM, which keeps the serving small (about 200 mg). Whether a single botanical matches multi-ingredient joint formulas has not been tested head to head.
Adjunct to lifestyle joint care
JointIQ® is intended as one component of an overall joint care approach that also includes appropriate physical activity, body-weight management, and clinical care of any underlying musculoskeletal conditions, rather than as a stand-alone therapeutic.
Mechanism of action
MMP inhibition and type II collagen support
Astragalus membranaceus root extract inhibits matrix metalloproteinases (MMP-3, MMP-13) and ADAMTS-5, the enzymes that break down cartilage matrix, and in laboratory studies increases type II collagen synthesis by chondrocytes. This is the proposed basis for its joint effects and comes from cell-culture work, not human tissue measurements.
Anti-inflammatory cytokine modulation
In TNF-alpha-stimulated human chondrocytes, the extract lowered IL-6, IL-1beta and IL-8 at the mRNA and protein level, without changing basal levels in unstimulated cells. These are cell-culture results, not measurements in people.
Astragalus phytochemistry and safety profile
Astragalus root contains saponins (astragalosides) and polysaccharides long used in traditional Chinese medicine, with a well-documented oral safety profile. The specific compounds responsible for the joint effects and the extract's standardization marker are not published on the public product page.
Clinical trials
Double-blind, randomized, placebo-controlled trial (Lippi 2025, Frontiers in Pain Research). 90 adults aged 18 to 60 with functional knee pain took 480 mg/day of a standardized Astragalus membranaceus root extract or placebo for 28 days. The investigational extract was owned by a different supplier (Giellepi S.p.A.), not confirmed to be the JointIQ material, and 480 mg is higher than the 200 mg JointIQ serving.
90 adults aged 18 to 60 with functional knee joint pain, in India.
The Astragalus group showed about a 30% reduction in knee pain on a visual analog scale after a 6-minute walk (mean fell from 6.7 to 1.2, p<0.0001), with improvements in WOMAC, stair-climb and range of motion, and no serious adverse events. This is one small 28-day trial; longer and JointIQ-specific studies are lacking.
Laboratory study in the HTB-94 human chondrocyte cell line (Mariano 2025, Current Issues in Molecular Biology). Astragalus membranaceus hydroalcoholic root extract was tested at 0.01 and 0.1 mg/mL against TNF-alpha-stimulated inflammation. One author was employed by the extract supplier (Giellepi S.p.A.).
Human chondrocyte cell line (HTB-94); in-vitro, with no human participants.
The extract reduced TNF-alpha-induced IL-6, IL-1beta, IL-8 and the matrix-degrading enzymes MMP-3, MMP-13 and ADAMTS-5, without altering basal levels in unstimulated cells. This is mechanistic cell-culture evidence, not a measured clinical outcome.